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MEASURING PATIENT PREFERENCES USING 
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Phillips KA1, O’Brien B2, Skolnik H1, Johnson TR3
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Conjoint analysis (CA) is one approach to measuring
preferences (“utilities”) that estimates both overall pref-
erences for goods or services as well as preferences for
their specific attributes. This method, derived from eco-
nomic theory, has been widely used in many fields, as it
can provide a more flexible format for preference mea-
surement than contingent valuation or QALYs. How-
ever, CA has not been as widely used in health care. An
unresolved issue is whether CA surveys can be made eas-
ier for respondents, thereby increasing their reliability
and validity. OBJECTIVE: We conducted an experiment
to assess whether surveys designed to be easier for re-
spondents would have greater reliability and validity
than surveys developed using the standard CA approach
where all levels of attributes are allowed to vary. METH-
ODS: We surveyed 300 respondents being tested for
HIV. Respondents were asked nine questions about
whether they would choose “Test A or B” based on six
attributes (location, cost, ease of collection, timeliness
and accuracy, confidentiality, counseling). We also asked
one repeated question and one dominated question (i.e.,
where respondents should choose the obvious choice). In
the standard survey, levels of all six attributes were al-
lowed to vary. In the easier version, levels of two at-
tributes stayed constant. RESULTS: Based on prelimi-
nary data, we found a trend towards the easier survey
having greater reliability and validity, as well as lower
subjective difficulty ratings. Further analyses will exam-
ine the tradeoffs between the decreased cognitive com-
plexity of the easier survey with the statistical efficiency
lost by forcing attributes to remain constant. CONCLU-
SION: CA can provide useful information on preferences
for attributes of goods and services, including pharma-
ceuticals. By simplifying the method used to obtain pref-
erences, it may be possible to obtain more reliable and
valid responses without sacrificing statistical efficiency. 
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ANALYSES: TOLTERODINE VERSUS 
OXYBUTININ XL FOR TREATING 
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OBJECTIVES: This study identifies and corrects the bias
in previous reports comparing tolterodine and oxybuti-
nin XL. By adjusting for different patient populations
used, the current study provides updated results. METH-
ODS: Using recent clinical trials, correction factors were
calculated to remove bias from previous efficacy esti-
mates. That bias resulted from failure to reconcile differ-
ences in the separate studies for the two drugs. Oxybuti-
nin XL trials included known responders, all with urinary
incontinence (UI), whereas tolterodine trials examined
both naïve and previously treated patients with overac-
tive bladder (OAB), some without UI. Therefore, mea-
sures of incontinence from the oxybutinin XL trials were
adjusted to levels appropriate for a naïve and previously
treated OAB population. To assess and correct the effect
of the bias, cost-effectiveness results were recalculated
based on corrected efficacy. The pharmacoeconomic
model from the previous analysis was not described in
sufficient detail to be used. Instead, it was simplified to
generate revised cost-effectiveness measures using re-
source and cost data from the previous analysis. RE-
SULTS: When adjusted, complete continence was 22.9%
for oxybutinin XL and 24.6% for tolterodine. The sim-
plified model then estimated 6-month treatment costs to
be $1684 for oxybutinin XL and $1661 for tolterodine.
Estimated costs per continent day were $45 and $42 re-
spectively. CONCLUSIONS: Cost-effectiveness analysis
can be misleading unless biases are explicitly identified
and corrected. After adjusting for limitations in the meth-
odology previously used, no significant differences in
cost-effectiveness remain between oxybutinin XL and
tolterodine. The corrected results are consistent with
findings from trials directly comparing oxybutinin XL
and tolterodine, which also found no efficacy differences.
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Kilburg A, Daniel D, Pfeil T, Kirchhoff D, Rychilk R
Institute of Empirical Health Economics, Burscheid, Germany
OBJECTIVE: In a cost-effectiveness analysis we compared
the socioeconomic relevance of adjuvant treatment of al-
coholic patients with acamprosate with different other
possible treatments but acamprosate. The main objective
was to reveal whether this adjuvant treatment is more cost-
effective compared to the control group considering direct
and indirect costs. Further objectives were to compare
the abstinence rate one year after the onset of the study,
the duration of abstinence until the next relapse and the
number of abstinent days during the observational pe-
riod. METHODS: In a prospective multicenter cohort
study we observed 1200 alcohol dependent patients over
a period of 12 months per patient, 800 patients in the acam-
prosate cohort, 400 in the control group. RESULTS: At
the end of the study data for 766 patients could be con-
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sidered in the statistical analysis (510 from the acampro-
sate cohort, 256 from the control group). The two
groups of the study population were comparable in terms
of sociodemographic variables. The number of abstinent
patients treated with acamprosate was 41.2% (per proto-
col analysis), only 25.4% (per protocol analysis) of all
patients in the control group were abstinent during the
study period. Although the drug costs are three times
higher in the acamprosate cohort the cost analysis re-
sulted in total costs of DM 3,026 ($1593) per patient/
year for the acamprosate group compared to DM 4,199
($2210) per patient/year in the control group, a signifi-
cant cost saving potential of DM 1,173 ($617). Hospital-
ization could be identified as the most cost-driving factor,
and was significantly higher in the control group. CON-
CLUSION: Based on the results of this study, it is sug-
gested that an initial expensive adjuvant treatment of al-
coholism leads to less cost than any other single therapy.
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A DECISION ANALYTIC MODEL MEASURING 
THE COST-EFFECTIVENESS OF HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY (HAART) IN HIV 
PATIENTS WITH HIGH VERSUS LOW BASELINE 
VIRAL LOAD: AN INDINAVIR PLUS LAMIVUDINE 
AND ZIDOVUDINE EXAMPLE
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OBJECTIVES: To quantify the cost-effectiveness of indi-
navir with zidovudine (ZDV) and lamivudine (3TC) com-
pared to ZDV3TC in patients with high and low base-
line viral load as cost per life-year gained (LYG) from a
third party payer perspective. METHODS: Progression
of HIV through 3 stages (CD4 200–500, CD4 200
No AIDS, AIDS) until death was modeled using a
Markov cycle tree, based on CD4 and viral load fac-
tors. Patients who failed to respond or progressed began
salvage therapy. Mortality, tolerability and disease pro-
gression rates were obtained from published sources. Six-
teen week clinical outcomes according to baseline viral
load (100,000 c/ml; 100,000 c/ml) were determined
from a randomized controlled trial (AVANTI II). Drugs
and medical care costs disaggregated by CD4 strata were
obtained from a Canadian HIV costing study. Future
costs and outcomes were discounted at 5%. RESULTS:
The incremental cost (1997 CDN $) per LYG with IDV/
ZDV/3TC vs. ZDV/3TC in patients with baseline viral
load below 100,000 c/ml was $68,353 per LYG. Indi-
navir/ZDV/3TC is more cost-effective in patients with
high baseline viral load (100,000 c/ml) at $24,852 per
LYG. The model was robust to probabilities and costs
tested in the sensitivity analysis. CONCLUSIONS: These
figures indicate that HAART therapies, such as indinavir/
ZDV/3TC provide important improvements at a reason-
able cost and thus are attractive both clinically and eco-
nomically, especially in patients with high baseline viral
load. Factors such as resistance and adherence to therapy
need to be considered in future models.
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INCORPORATING BOTH DIASTOLIC AND 
SYSTOLIC PRESSURES IN A MODEL OF THE 
BENEFITS OF ACHIEVING HYPERTENSION 
TREATMENT TARGETS
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Models of the clinical and economic impact of hyperten-
sion and the benefits of blood pressure (BP) control typi-
cally focus on either diastolic or systolic blood pressure
(DBP or SBP) but not both. For example, our previously-
reported Hypertension Burden of Illness Model consid-
ered only DBP and therefore could not address the issue
of systolic hypertension. OBJECTIVE: To estimate the
clinical and economic benefits of achieving both DBP and
SBP goals in treated hypertensives. METHODS: We re-
vised and updated our existing model which was de-
signed to forecast cardiovascular disease (CVD) incidence
and direct medical-care costs for specified populations,
such as the membership of a managed-care plan, and
simulates the effect of programs to improve BP control.
The underlying Framingham Heart Study (FHS) risk
equations, which previously quantified the relationship
between DBP and CVD risk, were replaced with new
FHS equations that incorporated both DBP and SBP. The
economic costs of CVD were estimated as in the earlier
version using major national health surveys and health-
care cost databases. RESULTS: We estimate that 9.6 mil-
lion persons aged 40–79 years in the US are treated for
hypertension but continue to have uncontrolled DBP
(90 mmHg) or SBP (140 mmHg). If all of these pa-
tients were treated to high-normal BP (140/90), an esti-
mated 414,000 CVD events would be prevented over 10
years resulting in medical care cost savings of $6.5 bil-
lion, an average of 43 events and $674,000 per 1000 pa-
tients. If such treatment were limited to patients with a
history of CVD, it would prevent an estimated 59 events
and save $761,000 per 1000 patients. CONCLUSION:
